TY  - JOUR
AU  - Fobelo Lozano, María José
AU  - Serrano Giménez, Reyes
AU  - Castro Fernández, Manuel
PY  - 2018
DO  - 10.1093/ecco-jcc/jjy063
UR  - http://hdl.handle.net/10668/12442
T2  - Journal of Crohn's & colitis
AB  - Secukinumab is an anti-IL 17A monoclonal antibody currently licensed for the treatment of plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis. However, although inflammatory bowel disease is a disorder with related immune...
LA  - en
KW  - IBD
KW  - Secukinumab
KW  - adverse effects; clinical trials
KW  - epidemiology
KW  - pathology
KW  - Antibodies, Monoclonal, Humanized
KW  - Female
KW  - Humans
KW  - Inflammatory Bowel Diseases
KW  - Male
KW  - Middle Aged
KW  - Psoriasis
KW  - Young Adult
TI  - Emergence of Inflammatory Bowel Disease During Treatment With Secukinumab.
TY  - research article
VL  - 12
ER  -